Skip to main content
Clinical Trials/NCT03683875
NCT03683875
Completed
Not Applicable

Ultrasonography of the Neuromuscular Degeneration Behavior in ALS: a Longitudinal Study

Hospital General Universitario Santa Lucia1 site in 1 country26 target enrollmentOctober 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Amyotrophic Lateral Sclerosis
Sponsor
Hospital General Universitario Santa Lucia
Enrollment
26
Locations
1
Primary Endpoint
Measuring echointensity of peripheral muscles using an ultrasound device
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal neurological disease.

An exhaustive and frequent clinical evaluation can lead to establish an adequate and early treatment of the consequences of its evolution.

Objectives.

  1. To evaluate the evolution of diaphragmatic and peripheral neuromuscular degeneration by ultrasound examination in patients with ALS and to establish possible evolution patterns.
  2. To verify the relationship between the degenerative peripheral and diaphragmatic neuromuscular changes evaluated by ultrasonography and changes in clinical scales frequently used.
  3. To compare the ultrasonographic features of subjects with ALS and a sample of healthy subjects Methods. A longitudinal observational study in a consecutive sample of patients diagnosed with ALS will be realized. All the patients will be examined 3 times, with an interval of at least 3 months between tests. Bilateral and cross sectional ultrasonography of several peripheral muscles and diaphragm will be performed at rest and during muscle contraction. All the images will be processed and analyzed for obtaining morphometric variables (muscle thickness) and textural ones (echogenic variation, entropy, homogeneity, textural contrast and correlation). Frequency of twitches will be also recorded in peripheral muscles.Also clinical features will be noted, every time of the 3 exams, from Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-r), British Medical Council Research Scale(MRC), and routine pulmonary tests.
Registry
clinicaltrials.gov
Start Date
October 1, 2018
End Date
March 10, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hospital General Universitario Santa Lucia
Responsible Party
Principal Investigator
Principal Investigator

Antonio Tomás Ríos-Cortés

Msc Physiotherapist

Hospital General Universitario Santa Lucia

Eligibility Criteria

Inclusion Criteria

  • Definite ALS

Exclusion Criteria

  • Primary Lateral Sclerosis (PLS)
  • Other forms of motor neuron disorders

Outcomes

Primary Outcomes

Measuring echointensity of peripheral muscles using an ultrasound device

Time Frame: 3 months

These measurements will be carried out in the biceps brachialis, forearm flexors, thenar eminence muscle, quadriceps and tibialis anterior which will be compared between patient with ALS and control group.

Thickness Fraction of the Diaphragm in ALS patients and control group.

Time Frame: 3 months

It is calculated as the difference between thickness at end inspiration and end expiration

Measuring thickness of peripheral muscles using an ultrasound device

Time Frame: 3 months

These measurements will be carried out in the biceps brachialis, forearm flexors, thenar eminence muscle, quadriceps and tibialis anterior which will be compared between patient with ALS and control group.

Measuring sonoelastography of peripheral muscles using an ultrasound device

Time Frame: 3 months

These measurements will be carried out in the biceps brachialis, forearm flexors, thenar eminence muscle, quadriceps and tibialis anterior which will be compared between patient with ALS and control group.

Diaphragmatic Excursion (quiet and forced) of the Diaphragm in ALS patients and control group

Time Frame: 3 months

Displacement of the right diaphragm dome

Secondary Outcomes

  • Measurement of muscle fasciculations using an ultrasound device(3 months)
  • Measurement of muscle strength using Medical Research Council Scale (MRCs)(3 months)
  • Measurement Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-r)(3 months)
  • Maximal Inspiratory Pressure (MIP)(3 months)
  • Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)(3 months)
  • Measuring Forced Vital Capacity(3 months)
  • Sniff- nasal inspiratory pressure (SNIP)(3 months)
  • Peak Cough Flow (PCF)(3 months)
  • Cumulative time percentage with SpO2 under 90% (CT90)(3 months)

Study Sites (1)

Loading locations...

Similar Trials